Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Organon (OGN – Research Report), with a price target of ...

Organon (NYSE:OGN) shares traded in the red on Friday, breaking a streak of six straight days of gains. Stock down 0.9% at ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

TD Cowen analyst Michael Nedelcovych took over primary coverage of Organon (OGN) with a Hold rating and $19 price target Organon presented ...

JERSEY CITY, N.J., December 19, 2024--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th Organon ...

Organon & Co (OGN) stock saw a decline, ending the day at $15.85 which represents a decrease of $-0.15 or -0.94% from the prior close of $16. The stock opened at $15.92 and touched a low of $15.75 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Organon (OGN) closed at $16 in the latest trading session, marking a +1.78% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.16%. Meanwhile, the Dow ...

周二，TD Cowen维持对Organon & Co. (NYSE:OGN)股票的"持有"评级，设定目标价为19.00美元。此举是在分析师覆盖从Steve Scala转移到Michael Nedelcovych之际。Organon最近分享了其业务运营的更新，其中包括对2025年的预测。